{
  "actions": [
    {
      "acted_at": "2018-04-17", 
      "action_code": "10000", 
      "references": [], 
      "text": "Introduced in Senate", 
      "type": "action"
    }, 
    {
      "acted_at": "2018-04-17", 
      "action_code": "", 
      "committees": [
        "SSFI"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Read twice and referred to the Committee on Finance.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "s2691-115", 
  "bill_type": "s", 
  "by_request": false, 
  "committee_reports": [], 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "Senate Finance", 
      "committee_id": "SSFI"
    }
  ], 
  "congress": "115", 
  "cosponsors": [
    {
      "bioguide_id": "B001277", 
      "district": null, 
      "name": "Blumenthal, Richard", 
      "original_cosponsor": false, 
      "sponsored_at": "2018-04-19", 
      "state": "CT", 
      "title": "Sen", 
      "withdrawn_at": null
    }, 
    {
      "bioguide_id": "G000555", 
      "district": null, 
      "name": "Gillibrand, Kirsten E.", 
      "original_cosponsor": false, 
      "sponsored_at": "2018-04-19", 
      "state": "NY", 
      "title": "Sen", 
      "withdrawn_at": null
    }, 
    {
      "bioguide_id": "H001075", 
      "district": null, 
      "name": "Harris, Kamala D.", 
      "original_cosponsor": true, 
      "sponsored_at": "2018-04-17", 
      "state": "CA", 
      "title": "Sen", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2018-04-17", 
  "number": "2691", 
  "official_title": "A bill to hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic in the United States.", 
  "popular_title": null, 
  "related_bills": [
    {
      "bill_id": "hr5782-115", 
      "identified_by": "CRS", 
      "reason": "identical", 
      "type": "bill"
    }
  ], 
  "short_title": "Opioid Crisis Accountability Act of 2018", 
  "sponsor": {
    "bioguide_id": "S000033", 
    "district": null, 
    "name": "Sanders, Bernard", 
    "state": "VT", 
    "title": "Sen", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2018-04-17", 
  "subjects": [
    "Business ethics", 
    "Business expenses", 
    "Business records", 
    "Child health", 
    "Civil actions and liability", 
    "Corporate finance and management", 
    "Department of Health and Human Services", 
    "Department of Justice", 
    "Department of Labor", 
    "Drug safety, medical device, and laboratory regulation", 
    "Drug trafficking and controlled substances", 
    "Drug, alcohol, tobacco use", 
    "Education programs funding", 
    "Elementary and secondary education", 
    "Employment taxes", 
    "Executive agency funding and structure", 
    "Government information and archives", 
    "Government studies and investigations", 
    "Government trust funds", 
    "Health", 
    "Health programs administration and funding", 
    "Health promotion and preventive care", 
    "Income tax credits", 
    "Marketing and advertising", 
    "Medical research", 
    "Preschool education", 
    "Prescription drugs", 
    "Research and development", 
    "Securities", 
    "Small business", 
    "Wages and earnings"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced in Senate", 
    "date": "2018-04-17T04:00:00Z", 
    "text": "Opioid Crisis Accountability Act of 2018\n\nThis bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks.\n\nThe bill penalizes drug manufacturers or distributors who illegally advertise, market or distribute an opioid product, including by (1) imposing a civil fine or salary confiscation, (2)revoking any remaining period of market exclusivity for such product, (3)requiring reimbursement of federal funding received for such product, and (4)prohibiting certain tax credits."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "A bill to hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic in the United States.", 
      "type": "official"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Opioid Crisis Accountability Act of 2018", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Opioid Crisis Accountability Act of 2018", 
      "type": "short"
    }, 
    {
      "as": null, 
      "is_for_portion": false, 
      "title": "Opioid Crisis Accountability Act of 2018", 
      "type": "display"
    }
  ], 
  "updated_at": "2019-07-16T21:20:11Z", 
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/115/s/BILLSTATUS-115s2691.xml"
}